Impaired Antitumor Immune Response inMYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment
Open Access
- 5 July 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (7) , 577-589
Abstract
In neuroblastoma, MYCN amplification is associated with sparse immune infiltrate and poor prognosis. Dendritic cells (DC) are crucial immune sentinels but their involvement in neuroblastoma pathogenesis is poorly understood. We observed that the migration of monocytes, myeloid and plasmacytoid DC induced by MYCN-nonamplified neuroblastoma supernatants was abrogated by the addition of anti-CCL2 antibodies, demonstrating the involvement of the CCR2/CCL2 axis in their recruitment by these tumors. Using public RNA sequencing and microarray datasets, we describe lower level of expression of CCL2 in MYCN-amplified neuroblastoma tumors, and we propose a working model for T-cell recruitment in neuroblastoma tumors in which CCL2 produced by neuroblastoma cells initiates the recruitment of monocytes, myeloid and plasmacytoid DCs. Among these cells, the CD1c+ subset may recruit T cells by means of CCL19/CCL22 secretion. In vitro, supernatants from DCs cocultured with neuroblastoma cell lines and activated contain CCL22 and CCL19, and are chemotactic for both CD4+ and CD8+ T cells. We also looked at immunomodulation induced by neuroblastoma cell lines, and found MYCN-nonamplified neuroblastoma cell lines were able to create a microenvironment where DC activation is enhanced. Overall, our findings highlight a major role for CCL2/CCR2 axis in monocytes, myeloid and plasmacytoid cells recruitment toward MYCN-nonamplified neuroblastoma, allowing further immune cell recruitment, and show that these tumors present a microenvironment that can favor DC responses.Significance: In MYCN-nonamplified neuroblastoma, CCL2 produced by neuroblastoma cells induces the recruitment of antigen-presenting cells (DCs and monocytes/macrophages), allowing infiltration by T cells, in link with CCL19 and CCL22 production, hence favoring immune responses.Keywords
All Related Versions
Funding Information
- Etablissement Français du Sang (N/A)
This publication has 57 references indexed in Scilit:
- Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma CellsJournal of Immunotherapy, 2013
- Immunology and immunotherapy of neuroblastomaSeminars in Cancer Biology, 2011
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastomaJournal of Clinical Investigation, 2007
- Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy NumberCancer Research, 2006
- Dendritic cell trafficking: More than just chemokinesCytokine & Growth Factor Reviews, 2005
- Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2Journal of Experimental Medicine, 2004
- Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cellsJournal of Leukocyte Biology, 2004
- Characterization of human blood dendritic cell subsetsBlood, 2002
- N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastomaCell, 1986